Any current/future new fundraising through debt or equity?

There is no mention of any immediate or planned new fundraising through debt or equity in the transcript. Current debt stands at about CHF 163 million as of March 31, 2024, with no significant increase expected going forward. The company is generating free cash flow starting FY'25, which should help reduce net debt over the next 2-3 years. Discussions are ongoing with banks regarding covenant waivers and possibly more favorable loan terms to reduce interest cost. No specific plans for raising fresh equity or debt were indicated; focus is on optimizing existing financial structure and operation

Any current/future capex/capital investment/strategic investment?

Most major capex programs have been completed, including those in France, Switzerland (co-investment projects), and Indian sites (Bavla and Naroda). Current CWIP (~INR500 crores) mainly includes capital expenditure for the second manufacturing line in France (expected operational during FY '25) and some digital transformation projects. FY '25 capex guidance is around $25-30 million, with approximately $18 million for maintenance capex and the remainder for completing digital transformation and some additional capex in Bavla and Naroda. No major new capex programs are planned beyond routine mai

Future growth expectations in sales/revenue/volumes?

India CRAMS business expected to ramp up significantly post regulatory clearances, targeting around INR350 crores revenue in FY '25, moving towards INR400-500 crores by FY '26-27. Overall CRAMS revenue (including French entity) projected to grow at 14-15% annually. Swiss entity expected to post 8-10% revenue growth in FY '25. UK entity projected to rebound strongly with 40-50% growth in FY '25 due to lower base last year. French facility, now operational after resolving technical issues, anticipated to ramp up revenue beyond the current ~$14 million in FY '25, contributing substantiall

Future growth expectations in earnings/operating earnings/profits/EPS?

Financial Year (FY) 2025 is expected to be significantly better than FY 2024 with normalization post France issues. Revenue growth guidance for FY 2025: 10-12% consolidated growth, driven by ramp-up in India and Bangladesh businesses, and recovery in UK and France. EBITDA margin target for FY 2025: 18-20%, improving due to reduced exceptional costs and raw material cost controls, especially in the Netherlands. Positive cash flow expected from FY 2025 onwards, with free cash flow around INR 400-500 crores. Net profit after tax (PAT) is expected to turn positive from FY 2026, considering

Current/ Expected Orderbook/ Pending Orders?

The company currently has development orders in excess of $140 million (page 17). There are already orders in hand for the French facility, with an additional $90 million of Requests for Proposal (RFP) out (page 27). The ramp-up of the India and Bangladesh businesses is expected to contribute significant order growth in H2 FY '25 (page 28). New customers are coming to the Bavla site post regulatory clearances, indicating increasing orders (page 20). Positive outlook on the Swiss entity's order book with expected consistent growth of 8-10% in revenues (page 18). Overall, the company expects muc

IN US

Sale is live|00:00:00left today

Dishman Carbogen Amcis LtdQ1 FY24Pharmaceuticals & Biotechnology

Dishman Carbogen Amcis Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹173P/E: 23.1Market Cap: ₹3.0K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→India CRAMS business expected to ramp up significantly post regulatory clearances, targeting around INR350 crores revenue in FY '25, moving towards INR400-500 crores by FY '26-27.
→Overall CRAMS revenue (including French entity) projected to grow at 14-15% annually.
→Swiss entity expected to post 8-10% revenue growth in FY '25.
→UK entity projected to rebound strongly with 40-50% growth in FY '25 due to lower base last year.
→French facility, now operational after resolving technical issues, anticipated to ramp up revenue beyond the current ~$14 million in FY '25, contributing substantially going forward.
→Total consolidated revenue growth target for FY '25 is around 10-12%.
→Ramp-up in second half of FY '25 expected to be faster than first half, with better quarterly performances post Q2.
→Innovation and new projects (e.g., vitamin D products) expected to contribute to revenue growth starting FY '26 onwards.

Margin guidance

Category 1

→Financial Year (FY) 2025 is expected to be significantly better than FY 2024 with normalization post France issues.
→Revenue growth guidance for FY 2025: 10-12% consolidated growth, driven by ramp-up in India and Bangladesh businesses, and recovery in UK and France.
→EBITDA margin target for FY 2025: 18-20%, improving due to reduced exceptional costs and raw material cost controls, especially in the Netherlands.
→Positive cash flow expected from FY 2025 onwards, with free cash flow around INR 400-500 crores.
→Net profit after tax (PAT) is expected to turn positive from FY 2026, considering a recurring goodwill write-off of INR 45 crores per annum.
→EBITDA losses in France expected to reduce from INR 100 crores (FY 24) to INR 35-40 crores (FY 25) and break even by FY 26.
→Capex for FY 25 guided at USD 25-30 million, mainly maintenance and digital transformation.
→Management aims for mid-to-high teens percentage revenue growth in CRAMS businesses in FY 25-26.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no mention of any immediate or planned new fundraising through debt or equity in the transcript.
→Current debt stands at about CHF 163 million as of March 31, 2024, with no significant increase expected going forward.
→The company is generating free cash flow starting FY'25, which should help reduce net debt over the next 2-3 years.
→Discussions are ongoing with banks regarding covenant waivers and possibly more favorable loan terms to reduce interest cost.
→No specific plans for raising fresh equity or debt were indicated; focus is on optimizing existing financial structure and operational cash flow generation.

Order book

Yes

→The company currently has development orders in excess of $140 million (page 17).
→There are already orders in hand for the French facility, with an additional $90 million of Requests for Proposal (RFP) out (page 27).
→The ramp-up of the India and Bangladesh businesses is expected to contribute significant order growth in H2 FY '25 (page 28).
→New customers are coming to the Bavla site post regulatory clearances, indicating increasing orders (page 20).
→Positive outlook on the Swiss entity's order book with expected consistent growth of 8-10% in revenues (page 18).
→Overall, the company expects much higher growth in the second half of FY '25 driven by order inflow and operational normalization (page 28).

Capex plans

Yes

→Most major capex programs have been completed, including those in France, Switzerland (co-investment projects), and Indian sites (Bavla and Naroda).
→Current CWIP (~INR500 crores) mainly includes capital expenditure for the second manufacturing line in France (expected operational during FY '25) and some digital transformation projects.
→FY '25 capex guidance is around $25-30 million, with approximately $18 million for maintenance capex and the remainder for completing digital transformation and some additional capex in Bavla and Naroda.
→No major new capex programs are planned beyond routine maintenance and a water purification plant in Bavla.
→Digital transformation is ongoing, including implementation of SAP and other digital tools to improve productivity.
→All capex is aimed at supporting growth, regulatory clearances, and operational improvements across sites.

How does Dishman Carbogen Amcis Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Dishman Carbogen Amcis Ltd

Rev 3Mar 1

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Dishman Carbogen Amcis Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio